Jean-Marc Lacombe
Overview
Explore the profile of Jean-Marc Lacombe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carrieri P, Bourliere M, Di Beo V, Lusivika-Nzinga C, Ramier C, Antwerpes S, et al.
Qual Life Res
. 2023 Aug;
32(12):3427-3438.
PMID: 37587323
Purpose: Hepatitis C virus (HCV) cure after treatment with direct-acting antivirals (DAAs) can improve health-related quality of life (HRQoL). However, specific groups with chronic HCV may still exhibit worse post-cure...
2.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Lacombe J, et al.
HIV Med
. 2021 Aug;
22(10):924-935.
PMID: 34402547
Objectives: HIV-coinfected patients experience higher incidences of non-liver-related cancers than HCV-monoinfected patients. Chronic inflammation, immunosuppression, but also higher tobacco or alcohol consumption and metabolic dysregulation could explain this higher risk....
3.
Costagliola D, Potard V, Lang S, Abgrall S, Duvivier C, Fischer H, et al.
J Acquir Immune Defic Syndr
. 2018 Nov;
80(2):214-223.
PMID: 30422911
Background: HIV-infected patients have lower bone mineral density and a higher incidence of fractures than the general population of the same age and sex. To assess the impact of antiretroviral...
4.
Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, et al.
AIDS
. 2018 Oct;
32(17):2605-2614.
PMID: 30289817
Objective: To assess CD4 recovery after combined antiretroviral therapy (cART) initiation with sustained virologic control. Design: Cohort study based on the French Hospital Database on HIV (FHDH-ANRS CO4). Methods: We...
5.
Potard V, Simon A, Lacombe J, Parienti J, Costagliola D
Clin Infect Dis
. 2016 Aug;
63(9):1254-1261.
PMID: 27543648
Background: In individuals with viral load (VL) suppression on a boosted protease inhibitor (PI) regimen, a switch to raltegravir (RAL) can be an option in case of comorbidities, but the...
6.
Supervie V, Marty L, Lacombe J, Dray-Spira R, Costagliola D
J Acquir Immune Defic Syndr
. 2016 Jun;
73(3):348-355.
PMID: 27351889
Background: Ensuring early universal access to HIV treatment is critical to reach the end of AIDS. The cascade of HIV care has become a critical metric to assess the coverage...
7.
Lang S, Lacombe J, Mary-Krause M, Partisani M, Bidegain F, Cotte L, et al.
PLoS One
. 2015 Jul;
10(7):e0133358.
PMID: 26200661
Background: The effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals have been discordant....
8.
Lacombe J, Goujard C, Valantin M, Cheret A, Lahoulou R, Girard P, et al.
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19781.
PMID: 25397525
Introduction: Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor available in France since 2006, is indicated for the treatment of HIV-1 infection in combination with a ritonavir boosted protease inhibitor (PI)...
9.
Costagliola D, Lacombe J, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, et al.
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19481.
PMID: 25393990
Introduction: A key objective of combined antiretroviral therapy (cART) is to reach and maintain high CD4 cell counts to provide long-term protection against AIDS-defining opportunistic infections and malignancies, as well...
10.
Delaugerre C, Ghosn J, Lacombe J, Pialoux G, Cuzin L, Launay O, et al.
Clin Infect Dis
. 2014 Oct;
60(3):463-72.
PMID: 25344539
Background: Calendar trends in virologic failure (VF) among human immunodeficiency virus (HIV)-infected patients can help to evaluate the performance of healthcare systems and the need for new antiretroviral therapy (ART)....